Moberg Pharma AB Interim Report January - March 2018

News provided by

Moberg Pharma

02:21 ET

STOCKHOLM, May 8, 2018 /PRNewswire/ -- SIGNIFICANT GROWTH FOR ALL KEY BRANDS

FIRST QUARTER (JAN-MAR 2018)

  • Net revenue SEK 91.5 million (104.6)
  • EBITDA SEK 21.9 million (16.7)
  • EBITDA margin 24% (16)
  • EBITDA for current product portfolio SEK 27.1 million (21.0)
  • Operating profit (EBIT) SEK 12.5 million (6.9)
  • Net profit after tax SEK 2.0 million (-3.0)
  • Diluted earnings per share SEK 0.12 (-0.17)
  • Operating cash flow per share SEK 0.66 (-0.17)

SIGNIFICANT EVENTS IN THE FIRST QUARTER

  • A favorable outcome was received from the National Advertising Division (NAD) in a challenge filed against the largest US
  • competitor to Kerasal Nail®. The competitor will discontinue its misleading packaging design and advertising
  • In February, an agreement was signed with Randob Labs to divest the brand Balmex® for a total consideration of USD 4.25
  • million (SEK 34.6 million) plus the inventory value at closing, generating a capital gain of approximately USD 0.5 million
  • (SEK 4.4 million)
  • The Nomination Committee proposes Anna Malm Bernsten as a n